anti-CD19/anti-CD3 bispecific antibody (Sichuan University)

N/A

Report date: 2026/03/19 16:57:19

Base Information

Drug Nameanti-CD19/anti-CD3 bispecific antibody (Sichuan University)

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionT cell surface glycoprotein CD3 stimulantsB-lymphocyte antigen CD19 inhibitors

TargetsB-lymphocyte antigen CD19T cell surface glycoprotein CD3

Therapy Area/IndicationsLymphoma, B-CellPrecursor Cell Lymphoblastic Leukemia-Lymphoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaPending

Originator CompaniesSichuan University

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesSichuan University

Active IndicationsN/A

Inactive IndicationsLymphoma, B-CellPrecursor Cell Lymphoblastic Leukemia-Lymphoma

Other Information

ATC CodeN/A